On March 22, 2024 Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") reported that it has entered into a comprehensive drug discovery collaboration agreement with the University of Oxford (Oxfordshire, UK; "Oxford") to verify drug discovery seeds and obtain screening compounds for the creation of innovative medicines (Press release, Ono, MAR 22, 2024, View Source [SID1234646257]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this comprehensive collaboration, Ono will select drug discovery seeds from the portfolio of Oxford that align with our research priority themes, and Oxford will conduct validation tests and compound screening for the drug discovery seeds at Oxford. First, Ono has selected the research theme relating to neuroscience, which is one of our four priority research areas and is also an expertise area at Oxford.

 More specifically, Oxford will conduct target validation experiments and compound screening, and Ono will generate drug candidates based on the compounds obtained from Oxford including their hit compounds, towards the development and commercialization of new drug candidates. Ono will obtain an option right to exclusively develop and commercialize these drug candidates worldwide.

 The University of Oxford, located in Oxfordshire, UK, is a collegiate university and one of the top universities in the world. It has the Centre for Medicines Discovery, which is focusing on drug discovery, and based on basic research by experts and researchers with deep insights into drug discovery seeds. It possesses the research infrastructure and drug discovery capabilities that enables to obtain highly unique drug discovery seeds and hit compounds for difficult-to-modulate target groups.

 Ono has generated a number of innovative medicines, by proactively promoting "open innovation", in the fields of cancer, immunology, neurology, and specialty area as priority areas for drug discovery. Ono keeps on committing to creating innovative medicines, aiming to become a global specialty pharma through our unique drug discovery approach based on the open innovation.

 "We are pleased to have the opportunity to collaborate with the University of Oxford, which possesses world-leading research capabilities." said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono. "We expect the potential for the development of new treatment through this partnership."

 "We are delighted to be starting this strategic collaboration with Ono Pharmaceuticals, to validate new therapeutic approaches across a range of different unmet medical needs. " said John Davis, Professor of Pharmaceutical Discovery, Centre for Medicines Discovery, the University of Oxford. "Combining innovative academic research together with the development insights and capability of pharmaceutical industry partners is key to unlocking the potential of new research findings"

On March 22, 2024 Acerand Therapeutics (Acerand) reported the successful completion of the first patient enrollment in the Phase 1/2 clinical trial (ACE-106-001) of their groundbreaking selective PARP1 inhibitor (ACE-86225106 tablets) (Press release, Acerand Therapeutics, MAR 22, 2024, View Source [SID1234641764]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ACE-106-001 is a first-in-human trial of Acerand’s self-developed selective PARP1 inhibitor ACE-86225106. This trial consists of two phases: dose escalation and backfill module in phase 1, followed by the dose expansion module in phase 2. The primary objective is to evaluate the safety, tolerability, PK/PD profile, and pre-liminary efficacy of ACE-86225106 as a monotherapy. The coordinating investigators leading this study are Professor Dingwei Ye and Jian Zhang from Fudan University Cancer Hospital. The study is being conducted simultaneously across multiple clinical institutions nationwide.

Remarks by Dr. Genshi Zhao, Acerand Co-Founder, President and CSO:

"This study is the first clinical trial of Acerand and represents a crucial milestone in our journey towards developing innovative small-molecule anti-tumor drug independently. While first-generation pan-PARP inhibitors have been approved for several indications (i.e., advanced ovarian, breast, prostate, and pancreatic cancers), their clinical optimal dose has been limited by adverse effects, limiting the therapeutic window. Highly selective PARP1 inhibitors hold promise in mitigating hematologic toxicity associated with PARP2 inhibition, potentially broaden the therapeutic window, enhancing patient compliance, and demonstrating improved efficacy."

About ACE-86225106：

ACE-86225106 is a novel, oral, and highly selective inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) developed independently by Acerand Therapeutics. It showed significant inhibitory effect on PARP1 in vitro, which was comparable with the positive controls (Olaparib, the first-generation pan-PARPi, and AZD5305, the second-generation PARP1 selective inhibitor under development), and showed no significant inhibitory effect on PARP2/3/5A/5B/6/7/12/14/15. In a DNA-PARP trapping assay, ACE-86225106 showed significant induction of DNA-PARP1 complex trapping, with no significant induction of DNA-PARP2 complex trapping, reaffirming its high PARP1 selectivity. Collectively, these findings suggest that compared to first-generation PARP inhibitors, ACE-86225106 is expected to uphold its anti-tumor efficacy with potentially reduced hematological toxicity risks (i.e. anemia) and extended therapeutic window, thereby improving the prognosis for patients with advanced solid tumor.

On March 22, 2024 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies working in the field of immune-oncology, reported the closing of the 2nd tranche of its previously announced non-brokered private placement (the "Offering") of units of the Company (the "Units") at a price of $1.50 per Unit for aggregate gross proceeds of $600,000.00 (the "Closing") (Press release, Defence Therapeutics, MAR 22, 2024, View Source;utm_medium=rss&utm_campaign=defence-completes-2nd-tranche-of-financing [SID1234641441]). Each Unit consists of one common share in the capital of the Company (each, a "Share") and one common share purchase warrant (each, a "Warrant").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each Warrant is exercisable to acquire one Share at an exercise price of $2.00 per Share on or before March 22nd, 2026 (the "Warrant Expiry Date").

In connection with the Closing, the Company paid a cash finder’s fee of $48,000.00 and issued 32,000 finder’s warrants (the "Finder’s Warrants") to a certain qualified arm’s length finder. Each Finder’s Warrant is exercisable into one Share at an exercise price of $2.00 per Share on or before the Warrant Expiry Date.

The Company intends to use the net proceeds of the Offering to advance its preclinical and clinical programs and for general working capital.

All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.

The securities being referred to in this news release have not been, nor will they be, registered under the United States (U.S.) Securities Act of 1933, as amended, and may not be offered or sold in the U.S. or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

On March 22, 2024 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, reported that new data highlighting the performance of its DecisionDx-Melanoma test in predicting risk of sentinel lymph node (SLN) positivity in patients with CM is being presented at the Society of Surgical Oncology 2024 (SSO 2024) Annual Meeting, being held March 20-23 in Atlanta (Press release, Castle Biosciences, MAR 22, 2024, View Source [SID1234641395]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have previously demonstrated that our DecisionDx-Melanoma test identifies patients who are eligible for an SLNB but have less than a 5% likelihood of being SLN positive, and could therefore consider avoiding the procedure," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We have also demonstrated that our test is a strong and independent predictor of metastasis. The study that was orally presented at SSO 2024 demonstrates that patients who did avoid an SLNB procedure had excellent outcomes to date. This demonstration is highly important as it showed that our test can help patients avoid an unnecessary procedure."

DecisionDx-Melanoma is supported by 50 peer-reviewed publications involving more than 10,000 patient samples, demonstrating its robust value in guiding risk-aligned patient care. The test has been designed and validated to inform two clinical questions in the management of melanoma: a patient’s risk of melanoma recurrence and metastasis, and their individual risk of SLN positivity, as highlighted in Castle’s SSO 2024 abstracts outlined below.

DecisionDx-Melanoma

Oral Presentation Number and Title: 62: Prospective validation of the i31-gene expression profile test for cutaneous melanoma to select patients who may consider foregoing sentinel lymph node biopsy
Session: Melanoma Parallel Session
Presenter and Lead Author: J. Michael Guenther, M.D., St. Elizabeth Physicians, Edgewood, Kentucky
Summary: This study shares three-year outcomes data from Castle’s prospective, multicenter study of patients with CM who were being considered for an SLNB (n=322). SLNB is an invasive surgical procedure used to determine whether a patient’s cancer has spread to nearby lymph nodes; the procedure returns a surgical result that is negative for metastasis in approximately 88% of patients. Current National Comprehensive Cancer Network guidelines use a 5% likelihood of SLN positivity as the threshold to avoid versus consider/recommend an SLNB due to an increased risk of metastasis. DecisionDx-Melanoma has been validated to provide a patient’s individualized risk of SLN positivity (i31-GEP for SLNB) by integrating clinical and pathologic risk factors with the patient’s tumor biology. In the study, no patients with a DecisionDx-Melanoma predicted risk of SLN positivity less than 5% had a positive SLN (among all tumor stages studied). If DecisionDx-Melanoma was used to inform management decisions, the test’s results could have further reduced the number of patients with T1-T2 tumors who could have avoided SLNB by 25%. Additionally, at three years, all patients with a low-risk DecisionDx-Melanoma test result were recurrence free (recurrence free survival of 100%). These data demonstrate that use of DecisionDx-Melanoma test results can guide accurate, risk-aligned clinical decision-making regarding the SLNB surgical procedure, within current guidelines. Further, the test can identify low-risk patients who can safely consider foregoing SLNB, thereby reducing unnecessary SLNB procedures (by approximately 25% in this study alone) and the associated costs and risks of complications that accompany them.

ePoster Number and Title: E309: Utility of 31-gene expression profile test in identifying patients with T1 cutaneous melanoma at high risk of SLN positivity and recurrence
Session: Melanoma Parallel Session

Summary: In a pooled cohort of 979 patients with thin (T1) tumors, a DecisionDx-Melanoma Class 2B result was the strongest predictor of a positive SLN, among other risk factors that included patient age, tumor location, Breslow thickness, tumor ulceration and more. While the study outlined above demonstrates the ability of the test to identify patients at low risk of SLN positivity who can safely forgo SLNB, this study shows that it can also identify patients at high risk who should consider it. By identifying patients who have a higher risk of SLNB positivity and recurrence, DecisionDx-Melanoma can help determine which patients should be considered for more intensive management, such as SLNB, increased follow-up frequency and imaging surveillance, to improve patient outcomes.

ePosters are available for conference attendees in the ePoster Online Gallery.

About DecisionDx-Melanoma

DecisionDx-Melanoma is a gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node (SLN) positivity and a patient’s personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma’s clinical value is supported by 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test’s results. Through Dec. 31, 2023, DecisionDx-Melanoma has been ordered more than 150,000 times for patients diagnosed with cutaneous melanoma.

On March 22, 2024 Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") reported promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic (Press release, Summit Therapeutics, MAR 22, 2024, View Source [SID1234641394]). Two posters featuring updated ivonescimab data will be displayed from 12:00 to 12:45pm Central European Time. The posters will also be made available on our website after the presentation period.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first poster, "Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases" includes data from patients with asymptomatic brain metastases at baseline. These patients were enrolled in either AK112-202 (NCT04900363), in which ivonescimab is delivered as monotherapy, or AK112-201 (NCT04736823), in which ivonescimab is delivered in combination with platinum doublet chemotherapy, both of which are Phase II clinical trials for patients with advanced or metastatic NSCLC. This analysis consisted of the 35 patients with advanced or metastatic NSCLC who had asymptomatic brain metastases at baseline; 28 patients were treated with ivonescimab plus chemotherapy in AK112-201, and seven patients were treated with monotherapy ivonescimab in AK112-202.

Notably, median intracranial progression-free survival was 19.3 months across all patients analyzed. Patients across both cohorts experienced an intracranial response rate of 34%, and eight patients (23%) experienced a complete response by RANO criteria. All patients who did not achieve a response demonstrated stable disease or non-progression; no patients experienced intracranial disease progression at the time of the initial follow-up scan. No cases of intracranial bleeding complications were observed in these patients.

"We are pleased to see ivonescimab’s favorable intracranial response rates and median intracranial progression-free survival as well as promising anti-tumor activity and safety profile in the subgroup of patients with brain metastases from NSCLC," said Dr. H. Jack West, Vice President of Clinical Development at Summit. "We are grateful for the patients and clinical investigators supporting these trials, and our ongoing collaboration with our partners at Akeso."

The second poster titled, "Phase 2 Results of Ivonescimab a Novel PD-1/VEGF Bispecific in Combination with Chemotherapy for First Line Treatment of Patients with Advanced / Metastatic Non-Small Cell Lung Cancer" includes updated data from the Phase II trial AK112-201 centered around the cohort of patients in which ivonescimab is combined with chemotherapy for first-line treatment of squamous and non-squamous advanced or metastatic NSCLC in patients without actionable genomic alterations (e.g., positive for endothelial growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK)). Summarized updates in NSCLC patients with EGFR mutations after a tyrosine kinase inhibitor (TKI) and NSCLC patients who have received prior PD-(L)1 plus doublet chemotherapy treatment are included as well.

Of significance, first-line advanced or metastatic squamous NSCLC patients experienced a median PFS of 11.1 months (95% CI: 9.5 – 16.3 months). In addition, first-line patients with advanced or metastatic non-squamous tumors experienced a median PFS of 13.3 months (95% CI: 8.3 – 16.4 months). Median overall survival was not reached in either subset of patients after a median follow-up time of 22.1 months. The frequency of treatment-emergent adverse events (TEAEs) leading to the discontinuation of ivonescimab was 11.1% and 2.8%, respectively, in patients with squamous and non-squamous tumors. The most frequent TEAEs were anemia and decreased neutrophil counts in squamous patients and anemia and constipation in non-squamous patients.

The posters will be presented by, amongst others, Dr. Li Zhang, Sun Yat-Sen University Cancer Center, and Dr. West, with data generated and analyzed by our collaboration and licensing partner, Akeso Inc. (HKEX Code: 9926.HK) with contribution by Summit staff.

Summit continues its clinical development of ivonescimab in order to establish its efficacy and safety in two NSCLC indications:

HARMONi Phase III trial: ivonescimab combined with chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR TKI (NCT05184712)
HARMONi-3 Phase III trial: ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (NCT05899608)
About the ELCC 2024 Posters

Poster Title: Phase 2 Results of Ivonescimab a Novel PD-1/VEGF Bispecific in Combination with Chemotherapy for First Line Treatment of Patients with Advanced / Metastatic Squamous Non-Small Cell Lung Cancer
ELCC Presentation No.: 68P
Session Date & Time: Friday, March 22, 2024, 12:00 to 12:45pm CET

Poster Title: Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer and Brain Metastases
ELCC Presentation No.: 174P
Session Date & Time: Friday, March 22, 2024, 12:00 to 12:45pm CET

About Ivonescimab

Ivonescimab, known as SMT112 in Summit’s license territories, the United States, Canada, Europe, and Japan, and as AK112 in China and Australia, is an investigational, novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays cooperative binding with each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF.

This could differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Ivonescimab’s tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the tumor microenvironment with over 18-fold increased binding affinity to PD-1 in the presence of VEGF in vitro, and over 4-times increased binding affinity to VEGF in the presence of PD-1 in vitro (Zhong, et al, SITC (Free SITC Whitepaper), 2023). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design is to improve upon previously established efficacy thresholds, in addition to side effects and safety profiles associated with these targets.

Ivonescimab was discovered by Akeso Inc. (HKEX Code: 9926.HK) and is currently engaged in multiple Phase III clinical trials. Over 1,600 patients have been treated with ivonescimab in clinical studies globally. Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), commencing enrollment in 2023 in two Phase III clinical trials.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.